EUVIMEDOpdag EUVIMED
Crossref

Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway

Nan Li, Zhenghua Zhang, Guodan Jiang, Honglan Sun, Deming Yu

Frontiers in Bioscience · 2019 · 24 (2) · 303-312

DOI: 10.2741/4719 ↗

At a glance

Journal article in Frontiers in Bioscience, 2019. Written by Nan Li and 4 co-authors. Institution: Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China. Cited 45 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Oxaliplatin is one of the most common chemotherapy drugs for colorectal cancer (CRC), but its application is greatly limited owing to the drug resistance. Nobiletin is a natural flavonoid isolated from citrus peel and has many biological functions, including anti-inflammatory, antitumor and neuroprotective activities. However, little is known about the effect of nobiletin on the anti-tumor activities of other chemotherapy drugs. In this study, we examined the effect of nobiletin on the efficacy of oxaliplatin in treatment of CRC by using two CRC cell lines. In vitro experiments indicated that nobiletin enhanced the inhibitory effect of oxaliplatin on the proliferation of CRC cells. Meanwhile, nobiletin promoted oxaliplatin-induced apoptosis of CRC cells, as demonstrated by the increased expression of pro-apoptotic proteins (Bax and cleaved-caspse3) and the down-regulation of anti-apoptotic protein Bcl-2. Mechanically, nobiletin sensitized CRC to oxaliplatin chemotherapy by down-regulating the PI3K/Akt/mTOR pathway. Taken together, our study has demonstrated that nobiletin could enhance the sensitivity of CRC to oxaliplatin chemotherapy, and provided a molecular basis for nobiletin's potential applications in the chemosensitization of CRC.

Subjects

MeSH terms (MEDLINE)

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalColorectal NeoplasmsDrug SynergismFlavonesHT29 CellsHumansOxaliplatinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine Kinases

Substances

Antineoplastic AgentsFlavonesOxaliplatinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasesnobiletin

Authors and institutions

  • Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.
  • Department of Oncology, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China, doxzzh@qq.com.
  • Department of General Surgery,Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.

Cite

APA

Li, N., Zhang, Z., Jiang, G., Sun, H., & Yu, D. (2019). Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway. Frontiers in Bioscience, 24(2), 303-312. https://doi.org/10.2741/4719

Vancouver

Li N, Zhang Z, Jiang G, Sun H, Yu D. Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway. Frontiers in Bioscience. 2019;24(2):303-312. doi:10.2741/4719

BibTeX
@article{Li2019,
  author = {Li, Nan and Zhang, Zhenghua and Jiang, Guodan and Sun, Honglan and Yu, Deming},
  title = {Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K Akt MTOR pathway},
  journal = {Frontiers in Bioscience},
  year = {2019},
  volume = {24},
  number = {2},
  pages = {303--312},
  doi = {10.2741/4719}
}
Start for free →